Press Releases
| 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
Newron and Zambon enter into a strategic collaboration and licence agreement for Safinamide
Newron Reports Completion of Phase III program for Safinamide in early and advanced Parkinson's disease patients
Newron Announces change in Management
Newron and Zambon extend option period for strategic collaboration and licence agreement for Safinamide in the EU and US to May 13, 2012
Jazz Pharmaceuticals Enters Definitive Agreement to Acquire EUSA Pharma
Cosmo shareholders elect new board and approve increased authority to buy back shares
The Economic Times: Infosys founder NS Raghavan's venture investing arm invests Rs 100 crore in Connexios
Connexios in discussions to partner early-stage GPR40 diabetes drug, CRO will be chosen in US/EU – CEO
Newron and Zambon enter into strategic collaboration and licence option for Safinamide in the EU and US
Cosmo Licenses Its Anti-Androgen for Certain Topical Applications
Cosmo reports strong 2011 financial and operational results -- Three drugs close to market -- Confident outlook for 2012
COSMO announces FDA acceptance of investigational new drug application for CB-03-01
Newron announces financial calendar for 2012
COSMO announces FDA acceptance of submission of new drug application for Uceristm (Budesonide) tablets by its licensee Santarus
Newron signs license agreement with Meiji Seika Pharma for Safinamide covering Japan and key Asian territories
EUSA Pharma Acquires Development and Commercialization Rights to ASPAREC® for Treatment of Acute Lymphoblastic Leukemia from Alizé Pharma
2012 R&D Day: Cosmo updates investors and analysts on progress and new developments in its R&D pipeline in Lainate
Newron to grant safinamide license to Meiji Seika Pharma for Japan and key Asian territories
COSMO announces FDA submission of New Drug Application for Uceristm (Budesonide) tablets by its licensee Santarus
Safinamide data to be presented at World Congress on Parkinson's disease and
related disorders in Shanghai
EUSA Pharma Announces FDA Approval Of Orphan Drug ERWINAZE™ For Treatment Of
Acute Lymphoblastic Leukemia
Newron Market Update
Newron is exploring all options for safinamide.Biotie acquisition discussions terminated
Newron regains full global rights to safinamide from
Merck Serono
Newron invites to Extraordinary General Meeting
Biotie to Acquire Newron Creating a Leading European Biopharmaceutical Company Focused on Central Nervous System Drug Development
Cosmo Announces Supportive Top-line Results From Budesonide MMX Extended Use Study
Newron Pharmaceuticals reports half-year results 2011
Newron: US IND for NW-3509 approved Potential add-on treatment for patients with schizophrenia
EUSA: FDA Continues BLA Review for EUSA Pharma’s ERWINAZETM
Newron: Completion of Patient Enrollment in SETTLE, a Phase III
Pivotal Clinical Trial of Safinamide in Advanced Parkinson’s Disease
Cosmo reports strong increase in revenues and profits
in first-half 2011 and substantial progress in development portfolio
Cosmo announces the additional approval of Lialda in the U.S. for the maintenance of remission in patients with ulcerative colitis
Newron submits US IND for NW-3509,a potential add-on treatment for patients with schizophrenia
Connexios Life Sciences Pvt. Ltd.- PreClinical Results - Bio Century Week in Review
Newron: Completion of Patient Enrollment in MOTION, a Phase III Pivotal Clinical Trial of Safinamide in Early Parkinson’s Disease
Preclinical Data on CNX-011-67 to be Presented at the 71st Scientific Sessions of the American Diabetes Association meeting San Diego,CA,June 24-28,2011
Cosmo Announces Very Positive Results of the First Parts of the Phase II Clinical Trials Following the Live Transmission of Blu-Colonoscopy at the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano.
Cosmo Announces Live Transmission of Blu-colonoscopy at the International Meeting for Advanced Gastrenterology Endoscopy at
Humanitas Hospital in Milano
Cosmo Announces Filing of Budesonide MMX® for Treatment of Mild to Moderate Active Ulcerative Colitis in Europe
F.D.A. Extends Priority Review of B.L.A. for EUSA Pharma’s ERWINAZETM By 90 Days
Newron’s Annual General Meeting Shareholders approve all motions of the Board of Directors
Data on Parkinson’s Disease Investigational Drug Safinamide to Be Presented at ANN 2011 Annual Meeting
Newron publishes AGM agenda --
Newron Pharmaceuticals reports 2010 results --
Newron and Merck Serono to Broaden Collaboration on New Therapies for Central Nervous System Diseases --
Cosmo reports good 2010 operational results -- Strategic goals met - Confident outlook for 2011 --
EUSA Pharma Erwinaze BLA awarded priority review Jan 2011 final
COSMO updates investors and analysts on progress and new developments in its R&D pipeline
EUSA Pharma Submits ERWINASE® Biologics License Application (BLA) for Treatment of Acute Lymphoblastic Leukemia
Cosmo announces positive top-line results in EU phase III clinical study evaluating Budesonide MMX in ulcerative colitis
Newron announces Top-Line Results of Long-Term Study of Safinamide as Add-on Treatment to Levodopa in Advanced Parkinson’s Disease
EUSA Pharma Announces 10-Year Outcome Data Demonstrating Utility of PROSTASCINT® in Guiding Prostate Cancer Radiotherapy and Improving Disease-Free Survival
Vantage Point - Indian scientists on quest for country's first novel molecule
Newron reports changes to Board of Directors and management
Cosmo reports exciting results in P.O.C. alopecia study
Newron reports half-year results 2010
Cosmo and Santurus announce positive top-line results in US phase III clinical study evaluating Budesonide MMX® in ulcerative colitis
EUSA Pharma announces the Appointment of Stephen A. Stamp to its Board of Directors
Cosmo reports increased revenues and operating profit in first-half 2010
Shire Files Suit against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc
EUSA Pharma Grants Japanese Rights To Erwinase® Oncology Therapy to Ohara Pharmaceutical
Newron: Data on Safinamide to Be Presented at the 14th MDS Meeting
Connexios: Harnessing the Indian cost advantage in network biology
Shire receives LIALDA® Paragraph IV Notice Letter from Zydus Pharmaceuticals
Newron reports SERENA trial top-line results for ralfinamide
Cosmo Pharmaceuticals announces drop in book value of shares of Santarus
BioCentry -Rolf Stahel sees scale in India
Newron’s Annual General Meeting Shareholders approve all motions of the Board of Directors
Ordinary and extraordinary assembly at BioXell
Connexios Aspires to Become the 'Jewel' of India's Biotechs
Bangalore based drug discovery group, Connexios Life Sciences, appoints Rolf Stahel as non-exectutive chairman
Cosmo reports good 2009 results -- Strategic goals met - Confident outlook for 2010 --
EUSA Pharma Completes Establishment of Commercial Infrastructure with Appointment of President for Europe and International Region
Bangalore based drug discovery group, Connexios Life Sciences, appoints Rolf Stahel as Non-Executive Chairman
Newron Pharmaceuticals reports 2009 results
Cosmo Pharmaceuticals announces preliminary end result of its tender offer for BioXell
Cosmo Pharmaceuticals announces preliminary interim result of its tender offer for BioXell
EUSA - New Informative Website Launched to Help People With Oral Mucositis and Their Carers
Newron completes enrolment in SERENA Phase IIb/III study of Ralfinamide in patients with Neuropathic Low Back Pain
Newron Reports Positive Pre-IND Meeting with FDA and MHRA for its NCE NW-3509 as an add-on to antipsychotics in patients with schizophrenia
NovaLead shows drug repositioning works
Chairman receives Lifetime Achievement Award from the BIA.
Cosmo announces strategic collaboration with Santarus for U.S. rights to Budesonide MMX® AND Rifamycin SV MMX®
Newron secures CHF30m long term standby equity line
Newron announces the approval for the Hunter-Fleming acquisition and appoints three new directors.
EUSA Pharma to Acquire US Specialty Oncology Company Cytogen
Seeking to build a new ecosystem for drug discovery
Cosmo announces preliminary full year results 2007
India Is Connexios’ Competitive Advantage
Kareus Therapeutics and Connexios announce a research collaboration
Newron acquires Hunter-Fleming Ltd
Rolf Stahel interview with Le Temps
Rolf Stahel appointed as Chairman of EUSA Pharma Inc. - EUSA acquires OPi SA, France
Rolf Stahel appointed non-executive Chairman of Cosmo Pharmaceuticals
The New Drug Discovery Partnerships
Pfizer to enter Vaccine Market through the acquisition of PowderMed
Connexios outsources literature curation to Molecular Connections
The Board of PowderMed Ltd. announces the appointment of Rolf Stahel as it's new non-executive Chairman
The Board of Cosmo S.p.A. announces the appointment of Rolf Stahel as its non-executive Deputy Chairman.
Newron Pharmaceuticals SpA announced the appointment of Rolf Stahel as non-executive Chairman.
Norwood Immunology Limited announced the Appointment of Rolf Stahel as non-executive Chairman.